106P - Efficacy and safety of bevacizumab in elderly patients with lung cancer adenocarcinoma

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Geriatric Oncology
Non-Small-Cell Lung Cancer, Metastatic
Presenter Konstantinos Syrigos
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors K.N. Syrigos, D. Vassos, M. Panagiotarakou, G. Tsoukalas, G. Athanasiadis, E. Sepsas, I. Gkiozos
  • Oncology Unit Gpp, Sotiria General Hospital, Athens School of Medicine, 115 27 - Athens/GR


Bevacizumab is a novel anti-angiogenic agent used in many advanced solid tumours, including non-squamous NSCLC. In contrast to clinical studies where enrolled patients are fit, many elderly NSCLC patients suffer from co-morbidities and often have history of a Cardiovascular Disease.